Fed. Sec. L. Rep. P 96,186 Securities and Exchange Commission v. Bausch & Lomb Incorporated and Daniel G. Schuman

565 F.2d 8, 1977 U.S. App. LEXIS 11325
CourtCourt of Appeals for the Second Circuit
DecidedSeptember 30, 1977
Docket11, Docket 76-6189
StatusPublished
Cited by104 cases

This text of 565 F.2d 8 (Fed. Sec. L. Rep. P 96,186 Securities and Exchange Commission v. Bausch & Lomb Incorporated and Daniel G. Schuman) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fed. Sec. L. Rep. P 96,186 Securities and Exchange Commission v. Bausch & Lomb Incorporated and Daniel G. Schuman, 565 F.2d 8, 1977 U.S. App. LEXIS 11325 (2d Cir. 1977).

Opinion

IRVING R. KAUFMAN, Chief Judge:

Many a corporate executive, conscious of the antifraud provisions of the Securities Acts, may analogize an encounter with a financial analyst to a fencing match conducted on a tightrope; he is compelled to parry often incisive questioning while teetering on the fine line between data properly conveyed and material inside information that may not be revealed without simultaneously disclosing it to the public. Exhorted by the Securities and Exchange Commission and the various stock exchanges 1 to divulge tidbits of nonpublic, “non-material” information, which may assume heightened significance when woven by the skilled analyst into the matrix of knowledge obtained elsewhere, the corporate representative will incur severe consequences if he discusses areas which are later deemed material. *10 But, since the importance of a particular piece of information depends on the context in which it is given, materiality has become one of the most unpredictable and elusive concepts of the federal securities laws. The SEC itself has despaired of providing written guidelines to advise wary corporate management of the distinctions between material and non-material information, and instead has chosen to rely on an after-the-fact, case-by-case approach, seeking injunc-tive relief when it believes that the appropriate boundaries have been breached. 2

In the instant case, it is clear that the appellee, Daniel G. Schuman, Chairman of the Board and the principal financial spokesman of Bausch & Lomb, Inc., violated the sanctum of materiality by divulging the corporation’s first quarter earnings forecast to an analyst on March 16, 1972. Nevertheless, we agree wholeheartedly with the conclusion of the able district judge, reached after an extensive hearing during which he observed the witnesses and adjudicated their credibility, that the SEC has failed to establish the essential predicate of injunc-tive relief — that there exists a reasonable likelihood of future wrongdoing by the ap-pellees. Accordingly, we affirm the district court’s order refusing to enjoin future violations of the securities laws.

I. THE FACTS

A. Bausch & Lomb Introduces Soflens

The fortunes of Bausch & Lomb, Inc. (“B & L”), one of the nation’s leading optical manufacturers, changed dramatically in March 1971, when it secured the Food and Drug Administration’s approval to market the first hydrophilic 3 soft contact lens in the United States. Because the new product, trade named “Soflens”, was more comfortable than the conventional hard contact lens, it was eagerly received by ophthalmic practitioners in a nationwide series of introductory symposia sponsored by B & L between May and November 1971. Soflens sales soon significantly increased B & L’s profits. Annual earnings grew 50 percent in 1971 compared to the previous year, and earnings in the last quarter of 1971 rose to $1.02 per share, almost triple those of the same quarter in 1970. The increment was almost completely attributable to Soflens.

As earnings skyrocketed, the value of B & L’s stock soared on the New York and Pacific stock exchanges. The price of a B & L share jumped from $46 in March 1971 to a peak of $194.75 on January 28, 1972, and B & L was dubbed a “glamor” stock. But, like any infatuation, the investment community’s love affair with B & L faded swiftly as Soflens’ imperfections became increasingly apparent during the first quarter of 1972.

B. B & L Stock Prices Plummet in Response to Adverse Publicity

Both analysts and B & L itself anticipated a decrease in sales of a 72-Soflens kit for practitioners after the final introductory symposium. Subsequent sales would consist primarily of replacement lenses. But, during the early months of 1972, So-flens faced less predictable, and more serious, difficulties. A primary source of concern among investors and within B & L itself was a spate of adverse publicity (“flak”) generated by broad coverage accorded medical studies indicating that soft contact lenses were not as safe and effective as conventional vision aids. The financial press reported that medical researchers had discovered substantial bacterial contamination of the Griffin lens, a soft contact lens manufactured by Frigitonics Inc. for the Canadian market, and that the American Optometric Association was questioning the sterility of Soflens itself. Rumors abounded that the FDA was contemplating withdrawal of its approval of So-flens, further prompting many analysts to *11 predict weakened consumer acceptance of the product.

The possibility of competition for Soflens proved even more damaging to B & L’s stature among investors. On February 23rd and 24th, 1972 the price of B & L shares dropped a total of 19Í/8 points, 11% of these on the 23rd alone, after the Wall Street Journal announced that E. I. du Pont de Nemours & Co. would enter the soft contact lens business. By the end of the month, B & L’s prospects had again darkened. On February 29th, Smith Barney & Co. analyst J. Gary Burkhead withdrew his “buy” recommendation on B & L. The next day, March 1st, B & L issued a press release stating that Soflens shipments had been halted by contamination in the shipping vials, and on that day alone B & L stock prices fell 17V2 points. During the three weeks preceding the week of March 13th, B & L plummeted a precipitous 40 points on the New York Stock Exchange. And, as that week began, reports that the Senate planned to investigate B & L’s monopolistic hold on the soft contact lens market circulated in the financial community.

C. March 15, 1972

Amid mounting investor concern about Soflens, Daniel G. Schuman, Chairman of B & L, embarked upon a series of interviews with financial analysts on March 15th. Although Schuman was reputed among analysts to be a poor source of information because of his extreme caution in discussing financial matters, intense interest in the impact of recent developments on B & L’s fate led several analysts to seek appointments with Schuman. Despite misgivings about the proposed meetings which had been arranged without his knowledge while he was vacationing, Schuman determined to proceed rather than appear to evade inquiries concerning the company’s declining fortunes. Not surprisingly, Schuman maintained his customary circumspect style during these sessions — only three of which need be discussed in detail.

1. The Sanders interview

On the afternoon of March 15th, Schu-man spoke with Lewis A. Sanders, an analyst with Sanford C. Bernstein & Co. Sanders proffered his earnings estimates of $5 for the year, and $.75 for the quarter, seeking Schuman’s appraisal. Schuman declined to comment, however, even though B & L’s own earnings projection for the first quarter, which he had received on March 13th, was $.74, strikingly close to Sanders’s.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Norton v. LVNV Funding, LLC
N.D. California, 2022
Veleron Holding, B.V. v. Stanley
117 F. Supp. 3d 404 (S.D. New York, 2015)
SEC v. Contorinis
Second Circuit, 2014
Securities & Exchange Commission v. Tambone
802 F. Supp. 2d 299 (D. Massachusetts, 2011)
Securities & Exchange Commission v. Miller
744 F. Supp. 2d 1325 (N.D. Georgia, 2010)
Securities & Exchange Commission v. Rorech
720 F. Supp. 2d 367 (S.D. New York, 2010)
Securities & Exchange Commission v. Levine
517 F. Supp. 2d 121 (District of Columbia, 2007)
Securities & Exchange Commission v. Lawbaugh
359 F. Supp. 2d 418 (D. Maryland, 2005)
Greenhouse v. MCG Capital Corp.
392 F.3d 650 (Fourth Circuit, 2004)
Greenhouse v. Mcg Capital Corporation
392 F.3d 650 (Fourth Circuit, 2004)
Universal City Studios, Inc. v. Reimerdes
111 F. Supp. 2d 294 (S.D. New York, 2000)
LL Capital Partners v. ROCKEFELLER CENTER PROPS.
921 F. Supp. 1174 (S.D. New York, 1996)
Securities & Exchange Commission v. Kaufman
835 F. Supp. 157 (S.D. New York, 1993)
Securities & Exchange Commission v. Hasho
784 F. Supp. 1059 (S.D. New York, 1992)
United States v. Paul A. Bilzerian
926 F.2d 1285 (Second Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
565 F.2d 8, 1977 U.S. App. LEXIS 11325, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fed-sec-l-rep-p-96186-securities-and-exchange-commission-v-bausch-ca2-1977.